As 2025 wraps up, the TriNetX team is reflecting on a year of milestones, among them, being named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies list this November. Earlier this year, TriNetX was also recognized among the Top 25 Healthcare Software Companies, and our TriNetX LIVE™ platform was a Best of Show finalist at SCOPE Europe.
These honors mean a lot to us, not because of the recognitions themselves, but because they reflect the work our team does every day alongside our healthcare partners and the researchers who rely on our platform to bring life-changing therapies to patients faster.
Making an Impact
When we think about what drives TriNetX, it always comes back to one thing: enabling a connected world where data and intelligence power improved human health. That vision is what led us to build TriNetX LIVE™, a globally federated platform that connects real-world data (RWD) from 318+ million patients across 9,200+ sites and 215+ healthcare organizations.
This isn’t just about the scale of the data, though that matters. It’s about what researchers can do with it. TriNetX LIVE™ harmonizes electronic health records (EHRs), lab results, genomics, and claims data into a privacy-compliant common data model. This means researchers can build precise patient cohorts and run real-time analyses that used to take months in days or even hours.
The impact? Drugs get to market faster. Trials become more efficient. And patients get access to potentially life-saving treatments sooner.
Real Problems, Real Solutions
We’re proud of the technology we’ve built, but what really excites us is seeing how it’s being used to solve actual challenges in clinical research. Here are a few examples:
Making recruitment smarter. In inflammatory bowel disease research, TriNetX developed a machine learning (ML) model to predict treatment escalation risk within 7 days. Based on retrospective data, the model predicted that trial enrollment conversion rates could increase from 33% to 85% for Crohn’s disease and up to 70% for ulcerative colitis. That’s the difference between struggling to fill a trial and actually getting it done.
For lupus trials, which need patients in active disease flare, we deployed digital waiting rooms powered by artificial intelligence (AI) and RWD. One client was able to identify 103 potentially eligible patients across 11 sites and seven studies. Instead of waiting for patients to come to them, they could proactively find patients who were already in the right disease state.
Catching disease earlier. Early detection can be the difference between life and death, especially for aggressive cancers. An AI model for pancreatic cancer TriNetX developed in collaboration with Beth Israel Deaconess Medical Center (BIDMC) and a leading research institution identified 87 predictive features that enable earlier detection beyond traditional screening guidelines. This model is currently being validated on a prospective cohort of 6 million patients. If it performs as expected, it could help catch pancreatic cancer at stages when treatment is more likely to succeed.
Reducing trial headaches. Anyone who’s worked on a clinical trial knows that protocol amendments are both costly and frustrating. By leveraging RWD and AI, we’ve helped clients reduce these amendments by up to 50%. That’s not just saving time and money; it’s keeping trials on track so patients can access new treatments faster.
We’ve also reimagined how site selection works. Instead of starting with known sites and trying to find the right patients there, we help researchers identify the right patients first, then find the sites where they’re already receiving care. In one collaboration with a major pharmaceutical company, this approach led to a 63% site acceptance rate with an average response time of just nine days.
Building more representative trials. Representation in clinical trials isn’t just an ethical imperative; it’s a scientific one. Different populations can respond differently to treatments, so we need representative data. Our platform enables identification of diverse patient populations, with 87% of patients having known race values and 75% having known ethnicity values (for those who had a visit in the last year). This makes it much easier to design trials that reflect the real-world populations who will ultimately use these treatments.
Beyond Individual Trials
The work happening on our platform extends far beyond any single study. To date, TriNetX RWD has supported more than 2,000 peer-reviewed publications across therapeutic areas like oncology, cardiology, neurology, and ophthalmology. These aren’t just papers in journals; they’re evidence that’s informing clinical practice, regulatory decisions, and health policy around the world.
That’s what keeps us motivated. Every query run on our platform, every cohort built, every analysis completed. It’s all contributing to a larger body of knowledge that’s advancing medicine.
What’s Next
We’re not slowing down. Early in 2026, we’ll be releasing some of our most ambitious enhancements yet to TriNetX LIVE™. One of the most exciting developments is the integration of technology that lets researchers interact with our platform conversationally. Imagine being able to ask complex questions about patient populations in natural language and getting sophisticated analyses back; no need to be an expert in query building. That’s the kind of accessibility we’re enabling.
Another major milestone is the enhancements to our Application Programming Interface (API) capabilities that will further power the solutions our partners are already building. These connections will allow API users to send study queries directly from their systems to TriNetX via codes or natural language, receiving real-time patient counts, feasibility data, and site intelligence without switching platforms—all seamlessly integrated within their existing workflows. The result is the removal of data silos, faster study planning, and smoother support for enterprise-wide digital initiatives.
We’re also continuing to invest in our site intelligence and patient identification capabilities, using AI to democratize access to RWD and turn complexity into clarity. The goal is to make every aspect of clinical research more intuitive, more efficient, and more effective.
A Thank You to Our Global Community
These recognitions as a Top 25 Healthcare Software Company, a Top 50 Healthcare Technology Company, and a Best of Show finalist at SCOPE Europe belong to more than just TriNetX.
- They belong to our healthcare organization partners who trust us with their data.
- They belong to the researchers who push the boundaries of what’s possible with real-world evidence (RWE).
- And they belong to every patient whose health record, stripped of identifiers and protected by privacy regulations, contributes to the discoveries that will help future patients.
As we look toward 2026 and beyond, we’re energized by the challenges ahead. Clinical research is getting more complex, but the tools to navigate that complexity are getting better too. We’re committed to being at the forefront of that evolution, building the platform and capabilities that will define the next generation of drug development.
Here’s to more innovation, more collaboration, and most importantly, better outcomes for patients everywhere.
About Steve Kundrot
Steve is a technology and business leader with over 20 years of experience in clinical research, health analytics, consulting, and software development. As Chief Operating Officer, he oversees TriNetX’s core operational functions and leads the development of a unified product roadmap designed to revolutionize clinical research and accelerate drug development by optimizing clinical trial design, enhancing post-market safety, and delivering research-grade data and evidence that enable and expedite regulatory approvals.